Skip to main content

Table 3 Cox regression model of multivariable analysis for OS and PFS

From: Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma

  OS PFS
HR 95% CI P value HR 95% CI P value
Gender
 Female 1    1   
 Male 1.175 0.658–2.100 0.586 0.907 0.564–1.461 0.689
Age
 ≤ 50 1    1   
 > 50 1.570 0.906–2.718 0.108 1.110 0.715–1.725 0.641
T stage
 T1 1    1   
 T2 1.496 0.450–4.979 0.511 1.096 0.424–2.835 0.850
 T3 1.564 0.504–4.853 0.439 1.294 0.541–3.095 0.562
 T4 3.239 0.870–12.056 0.080 4.012 1.462–11.007 0.007
N stage
 N0 1    1   
 N1 4.041 0.533–30.616 0.176 2.162 0.650–7.190 0.208
 N2 5.758 0.762–43.511 0.090 3.081 0.931–10.199 0.065
 N3 10.354 1.219–87.914 0.032 7.165 1.924–26.678 0.003
Nimotuzumab
 Without 1    1   
 With 0.124 0.017–0.902 0.039 0.511 0.223–1.173 0.113